{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:08:35Z","timestamp":1793045315072,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.coi.2026.102770","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:49:49Z","timestamp":1776710989000},"page":"102770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms"],"prefix":"10.1016","volume":"100","author":[{"given":"Ecem","family":"Sevim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep B","family":"Erton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doruk","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102770_bib1","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102770_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102770_bib3","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.41891","article-title":"Expert perspective: management of microvascular and catastrophic antiphospholipid syndrome","volume":"73","author":"Erkan","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/hematology.2019000073","article-title":"Is there a role for immunosuppression in antiphospholipid syndrome?","volume":"2019","author":"Sevim","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.coi.2026.102770_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102212","article-title":"Treatment advances in antiphospholipid syndrome: 2022 update","volume":"65","author":"Erton","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.coi.2026.102770_bib6","series-title":"Dorland's Illustrated Medical Dictionary","author":"Dorland","year":"2012"},{"key":"10.1016\/j.coi.2026.102770_bib7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102770_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0032-1304718","article-title":"Update on the catastrophic antiphospholipid syndrome and the \"CAPS Registry\"","volume":"38","author":"Cervera","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.coi.2026.102770_bib9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/acr.24468","article-title":"Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository","volume":"74","author":"Sevim","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.coi.2026.102770_bib10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1172\/JCI39828","article-title":"Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via \u03b22GPI and apoER2","volume":"121","author":"Ramesh","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2026.102770_bib11","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.jacc.2017.02.058","article-title":"Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics","volume":"69","author":"Corban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coi.2026.102770_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clim.2004.02.015","article-title":"Endothelial cell activation by antiphospholipid antibodies","volume":"112","author":"Meroni","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1538-7836.2007.02310.x","article-title":"Platelet adhesion to dimeric \u03b22-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ib\u03b1 and apolipoprotein E receptor 2","volume":"5","author":"Pennings","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102770_sbref14","first-page":"219","article-title":"Mechanisms sensitive to different drugs mediate a pro-adhesive and pro-thrombotic platelet phenotype in anti-phospholipid syndrome","volume":"111","author":"Camera","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.coi.2026.102770_bib15","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/jth.15417","article-title":"Effect of heparanase inhibitor on tissue factor overexpression in platelets and endothelial cells induced by anti-\u03b22-GPI antibodies","volume":"19","author":"Capozzi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102770_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/cei.13248","article-title":"Tissue factor over-expression in platelets of patients with anti-phospholipid syndrome: induction role of anti-\u03b22-GPI antibodies","volume":"196","author":"Capozzi","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2014-02-554980","article-title":"Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS","volume":"124","author":"Proulle","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102770_bib18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2019001530","article-title":"Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis","volume":"134","author":"M\u00fcller-Calleja","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102770_bib19","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib20","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/art.41460","article-title":"Anti\u2013neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome","volume":"72","author":"Zuo","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib21","article-title":"Beta 2 glycoprotein I and neutrophil extracellular traps: potential bridge between innate and adaptive immunity in anti-phospholipid syndrome","volume":"13","author":"Grossi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib22","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/art.39576","article-title":"Low-density granulocytes are increased in antiphospholipid syndrome and are associated with anti\u2013\u03b22-glycoprotein i antibodies: comment on the article by Yalavarthi et al","volume":"68","author":"van den Hoogen","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib23","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody\u2013mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102770_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102770_sbref26","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14186672","article-title":"Activated complement system\u2019s impact in antiphospholipid syndrome thrombosis: from pathophysiology to treatment","volume":"14","author":"Tagara","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102770_bib27","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus formation induced by antibodies to \u03b22-glycoprotein I is complement dependent and requires a priming factor","volume":"106","author":"Fischetti","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102770_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00773","article-title":"Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid syndrome","volume":"10","author":"Lonati","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib29","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2026.102770_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/MBC.0b013e32830f1b85","article-title":"Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C","volume":"19","author":"de Laat","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.coi.2026.102770_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/WHE.10.2","article-title":"Risk quantification in antiphospholipid syndrome","volume":"6","author":"Erkan","year":"2010","journal-title":"Women's Health"},{"key":"10.1016\/j.coi.2026.102770_bib33","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3899\/jrheum.081194","article-title":"Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus","volume":"36","author":"Danowski","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/ATVBAHA.108.182204","article-title":"Venous thrombosis in the antiphospholipid syndrome","volume":"29","author":"Farmer-Boatwright","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.coi.2026.102770_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14030733","article-title":"Antiphospholipid syndrome: a comprehensive clinical review","volume":"14","author":"Patriarcheas","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102770_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.5152\/eurjrheum.2020.20058","article-title":"New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome","volume":"8","author":"Fujieda","year":"2021","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib37","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jth.12865","article-title":"Antiphospholipid syndrome: antibodies to Domain 1 of \u03b22\u2013glycoprotein 1 correctly classify patients at risk","volume":"13","author":"Pengo","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102770_sbref38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3899\/jrheum.2022-1200","article-title":"Efforts to better characterize \"Antiphospholipid Antibody Nephropathy\" for the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria: Renal Pathology Subcommittee Report","volume":"51","author":"Barbhaiya","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102770_sbref40","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.3390\/ijms26062750","article-title":"Activation of the mammalian target of rapamycin pathway in endothelial cells in antiphospholipid antibody-positive patients with leg ulcers","volume":"26","author":"Kov\u00e1cs","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2026.102770_sbref41","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.125.073552","article-title":"Microvascular endothelial cells license APS vasculopathy through YAP1- and CCN2-mediated signaling","volume":"152","author":"Shi","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.coi.2026.102770_sbref42","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1093\/rheumatology\/keae397","article-title":"Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and NETs-related gene expression","volume":"63","author":"Tektonidou","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102770_bib43","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coi.2026.102770_bib44","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102770_bib45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.ajkd.2019.08.032","article-title":"mTORC pathway activation and effect of sirolimus on native kidney antiphospholipid syndrome nephropathy: a case report","volume":"76","author":"Dufour","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.coi.2026.102770_bib46","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3899\/jrheum.220049","article-title":"Mammalian target of rapamycin pathway assessment in antiphospholipid antibody\u2013positive patients with Livedo","volume":"49","author":"Sevim","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib47","first-page":"510","article-title":"Pathogenesis of the obstetric antiphospholipid syndrome: the key role of beta 2 glycoprotein I","volume":"2","author":"Luigi","year":"2022","journal-title":"Explor Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0321405","article-title":"Beyond antibodies: beta-2 glycoprotein I as the unsung guardian of pregnancy","volume":"20","author":"Yagi","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2026.102770_bib49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102770_bib50","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/humrep\/17.4.1067","article-title":"Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure","volume":"17","author":"Sebire","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.coi.2026.102770_bib51","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajog.2024.03.010","article-title":"Systemic lupus erythematosus is associated with an increased frequency of spontaneous preterm births: systematic review and meta-analysis","volume":"231","author":"Abheiden","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.coi.2026.102770_bib52","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.autrev.2015.01.008","article-title":"Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature","volume":"14","author":"Viall","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102770_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.957201","article-title":"Circulating immune-complexes of IgG\/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome","volume":"13","author":"Naranjo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","article-title":"A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome","volume":"41","author":"Erkan","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102770_sbref55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1722080","article-title":"Immune-mediated mechanisms and maternal-fetal interface dysfunction in obstetric antiphospholipid syndrome","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/rheumatology\/keac264","article-title":"Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications","volume":"62","author":"Shi","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102770_sbref57","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1055\/a-2510-6147","article-title":"Association of specific antiphospholipid antibodies to platelet count and thrombocytopenia","volume":"125","author":"Griem","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102770_bib58","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/0961203314531347","article-title":"Pre-eclampsia as a manifestation of antiphospholipid syndrome: assessing the current status","volume":"23","author":"Gibbins","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102770_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.06.064","article-title":"Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression","volume":"205","author":"Wu","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.coi.2026.102770_bib60","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/rheumatology\/keac650","article-title":"Thrombocytopaenia in antiphospholipid syndrome: a free radical perspective","volume":"62","author":"Ames","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102770_bib61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/BOR.0000000000000595","article-title":"Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome","volume":"31","author":"Vreede","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib62","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/jcm13030741","article-title":"Platelets and thrombotic antiphospholipid syndrome","volume":"13","author":"Tohidi-Esfahani","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102770_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1459842","article-title":"Cell-bound complement activation products in antiphospholipid antibody-positive patients without other systemic autoimmune rheumatic diseases","volume":"15","author":"Erkan","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib64","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/ATVBAHA.123.318978","article-title":"Activation of platelet mTORC2\/Akt pathway by anti-\u03b22GP1 antibody promotes thrombosis in antiphospholipid syndrome","volume":"43","author":"Tang","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coi.2026.102770_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101015","article-title":"Hematological manifestations of antiphospholipid syndrome: going beyond thrombosis","volume":"58","author":"El Hasbani","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.coi.2026.102770_bib66","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1191\/0961203306lu2336oa","article-title":"Autoimmune hemolytic anaemia in the antiphospholipid syndrome","volume":"15","author":"Rottem","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102770_bib67","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"The antiphospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102770_bib68","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1111\/j.1537-2995.2008.01877.x","article-title":"Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance","volume":"48","author":"Staropoli","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2026.102770_sbref69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/09612033251332258","volume":"34","author":"Erton","year":"2025","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102770_bib70","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1055\/s-0039-1692702","article-title":"Cardiac manifestations of antiphospholipid syndrome: clinical presentation, role of cardiac imaging, and treatment strategies","volume":"45","author":"Tufano","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.coi.2026.102770_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00941","article-title":"Cardiac manifestations of antiphospholipid syndrome with focus on its primary form","volume":"10","author":"Kolitz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102770_bib72","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-013-0320-8","article-title":"Valvular heart disease in antiphospholipid syndrome","volume":"15","author":"Zuily","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.coi.2026.102770_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210485","article-title":"Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use","volume":"75","author":"van den Hoogen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102770_bib74","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102770_bib75","first-page":"597","article-title":"Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and\/or non-criteria manifestations of antiphospholipid syndrome: study protocol","volume":"41","author":"Sciascia","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_sbref76","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ard.2025.02.012","article-title":"Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial","volume":"84","author":"Branch","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102770_bib77","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/art.42017","article-title":"Defibrotide inhibits antiphospholipid antibody-mediated neutrophil extracellular trap formation and venous thrombosis","volume":"74","author":"Ali","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102770_bib78","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1161\/CIRCRESAHA.114.303312","article-title":"Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis","volume":"114","author":"Knight","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.coi.2026.102770_sbref79","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jtha.2024.09.024","article-title":"Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"23","author":"Friedberg","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102770_bib80","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1111\/bjh.16266","article-title":"Chimeric antigen receptor T-cell therapy's role in antiphospholipid syndrome: a case report","volume":"188","author":"Schmelz","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:24:42Z","timestamp":1779510282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":80,"alternative-id":["S0952791526000476"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102770","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding antiphospholipid syndrome clinical phenotypes with the guidance of antiphospholipid antibody-related pathogenic mechanisms","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102770"}}